Overview of the [corrected] travoprost /timolol BAK-free fixed combination.
Τίτλος | Overview of the [corrected] travoprost /timolol BAK-free fixed combination. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Konstas, A. G. P., Quaranta L., & Realini T. |
Journal | Expert Opin Pharmacother |
Volume | 13 |
Issue | 5 |
Pagination | 757-66 |
Date Published | 2012 Apr |
ISSN | 1744-7666 |
Λέξεις κλειδιά | Animals, Antihypertensive Agents, Benzalkonium Compounds, Cloprostenol, Drug Combinations, Glaucoma, Humans, Preservatives, Pharmaceutical, Timolol |
Abstract | INTRODUCTION: Glaucoma is the second leading cause of blindness globally, representing a significant public health concern. More than 60 million people are affected by glaucoma worldwide; as this population ages, the number is expected to increase. Glaucoma is a collection of heterogeneous diseases sharing common clinical characteristics. The goal of treatment is to prevent significant visual dysfunction through reduction of intraocular pressure (IOP).AREAS COVERED: This is a review of the current literature about combination therapeutic regimens for the reduction of IOP, focusing on the risk : benefit profile of a fixed-combination therapy using travoprost and timolol.EXPERT OPINION: Since the debut of prostaglandin analogues in the 1990s, only modest innovation has occurred in glaucoma pharmacology. A growing body of research has established that the preservative benzalkonium chloride (BAK) might not be the benign contributor expected of excipient ingredients. Thus, BAK-free treatments were developed, with the goal of IOP reduction without furthering ocular surface disease symptoms. The BAK-free travoprost/timolol combination represents an important addition to glaucoma medication options and may fill an unmet need in this therapeutic arena. |
DOI | 10.1517/14656566.2012.662485 |
Alternate Journal | Expert Opin Pharmacother |
PubMed ID | 22360540 |